A Prospective, Randomized, Double-Blinded, Sham-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of IDCT in Subjects With Single-Level, Symptomatic Mild to Moderate Lumbar Intervertebral Disc Degeneration
Latest Information Update: 17 Dec 2025
At a glance
- Drugs Rebonuputemcel (Primary)
- Indications Intervertebral disc degeneration
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PIVOT
- Sponsors DiscGenics
Most Recent Events
- 03 Dec 2025 Planned initiation date (estimated date of first participant enrollment) changed from 24 Nov 2025 to 30 Dec 2025.
- 03 Dec 2025 Status changed from not yet recruiting to recruiting.
- 28 Nov 2025 Status changed from planning to not yet recruiting.